



# HFMA/NEHIA 2025 Compliance & Internal Audit Conference

Wednesday, December 3 - Friday, December 5, 2025 Mystic Marriott Hotel, Groton, CT

#### **Tufts**Medicine

# HFMA / NEHIA Joint 2025 Compliance & Internal Audit Conference

CCO Perspectives on Artificial Intelligence: Regulatory Issue Spotting, Best Practices for Governance and Controls & Vendor Selection and Management

Garrett Gillespie, Chief Compliance Officer, Tufts Medicine December 5, 2025






# **Artificial Intelligence – CCO Perspective: Issue Spotting, Governance, Controls, Vendor Management**

- Recommended overall approach to AI: balance enthusiasm with prudence
- Al issue spotting for Healthcare Entities
- Establishing Initial Al Governance and Controls:
  - Al Use Policy
  - Responsible Al Committee
  - Al Strategy Committee
  - Al Product and Vendor Management



#### **Balance Enthusiasm with Prudence**

- Key takeaway: Al scales benefits and scales risks
- Let's proceed and pursue value-adding new technologies...
- with a good process that includes management governance, crossfunctional participation, and appropriate controls,
- And let's be humble and curious about what we don't know.



Demis Hassabis, CEO and co-founder of Google DeepMind: "I'm
 optimistic that we'll get this right, as long as we approach it in the
 right way, actually, using the scientific method and trying to be very
 thoughtful about each step that we take[.]"



#### Al Issue Spotting for Healthcare Entities

- Al-specific laws, regulation & guidance:
  - **Legislation/regulation**: states and federal agencies have taken the lead so far on legislation and regulatory guidance.
  - Focus so far: medical device requirements, consumer protection, accuracy of product claims, bias & discrimination, transparency, utilization management (CMS), use in employment.
- **Billing and coding**: if the product could impact billing, need to validate accuracy.
- Contracts: address who bears what risks, study the warranties and reps re: product.
- Data rights/privacy: consider who owns the data, how will it be used.
- FDA device requirements: understand what the intended uses of the product are, and whether the product might evolve.



## Al Issue Spotting for Healthcare Entities, cont.

- Governance & decision-making: need structure and process.
- Healthcare regulations and AI: issues include: corporate practice, medical board licensure and discipline, telehealth & AI (both have state-by-state regulation)
- **IP**: consider who owns the product, product improvements, and the outputs. Be mindful of user agreements (and how they can change).
- Liability & insurance: consider both the organization and practitioners.
- Quality processes: for manufacturers, but customers should consider:
  - Protocols, controls, documentation,
  - Human-in-the-loop,
  - Auditing and monitoring (pre-launch, pilots, post-launch),
  - Reporting & quality feedback loops
- **Security**: cybersecurity controls



# **Establishing Initial AI Governance and Controls**

#### **Key Concepts:**

- Just start.
- We don't have to be perfect to be good, and good is a lot better than nothing.

#### First elements:

- Al Use Policy
- Responsible Al Committee
- Al Strategy Committee
- Al Product and Vendor Management



#### **AI** Acceptable Use Policy

 Just start: publish a B+ policy with key concepts now versus waiting a several months to develop an A+ policy.

#### Key concepts to include:

- Users are (1) responsible for <u>not</u> inappropriately inputting sensitive data and (2) accountable for outputs and verifying their accuracy.
- Privacy and security rules still apply (no Al HIPAA exception): Minimum necessary, business associate agreements, proper de-identification.
- Contracting: set a mechanism for review & approval of AI products, watch out for who has data rights and whether vendor seeks to train its model with your PHI.
- Specific uses to address in the policy: e.g., clinical use, LLMs, AI meeting transcription tools/bots.



#### Responsible Al Committee

- **Get-stuff-done group**: Assemble a small group of subject matter experts (SMEs) who can quickly assess and take action.
- Key components:
  - The who:
    - Should be collaborative, practical, cross-functional leaders who can think strategically.
    - Consider IT (cyber, applications), clinical (CMIO), compliance (controls, process), and Risk. Depending on your team, can include or consult an AI SME and Legal.
  - The what (first charge):
    - Evaluate and make decisions (tactical) regarding proposed Al product/functionalities.
    - Implement initial controls.
  - Reporting: Develop a reporting cadence to key senior leaders and Al Strategy Committee.



## **AI Strategy Committee**

- Strategy & decision-making group: senior leaders who can set strategy and make decisions (big picture, material) for the organization, including:
  - Focus: what are the key problems to solve?
  - Costs, benefits, and resources
  - Build or buy? If buy, pursue a potential JV/partnership (with, e.g., economic participation), or a standard vendor engagement.
  - IP commercialization.
- Support thoughtful and efficient organizational decision-making by evaluating and **funneling** the best innovative-technology proposals to senior decision makers.
- Guide and support the development of appropriate controls and confirm their implementation
- Assign tasks to Responsible Al Committee and receive reports.



# Examples of AI controls for Ambient AI: Pilot with initial auditing & follow-up monitoring

- **Data**: understand and test the security, data collection, use, storage, and access. Leverage existing security risk assessment process.
- Auditing and monitoring: conduct a pilot and initial audit of the product's performance, including its accuracy, reliability, and safety:
  - Before broad launch, evaluate product re: e.g., clinical impact & documentation and revenue/expense/billing impact. Tailor audit to the product.
  - Monitor and test products post launch for continuous learning and adaptation.
- Consent: create processes to obtain and manage consents, where appropriate.
- Policy: describe how AI can be used & product-approval processes.
- User training: educate and reinforce controls.



# Al Product and Vendor Management: Governance mechanisms

- Proactive: Develop a process to seek out the AI products that will solve the problems you identified.
- Reactive: Create an intake mechanism (single pipe) for internal requests to use AI products and vendor proposals. May be able to leverage existing IT processes such as request forms and portals.

#### Approval process:

- Develop written criteria to uniformly assess and approve AI vendors and products. Document and retain your evaluations.
- Process could flow through an existing IT tool with the addition of an Alspecific addendum.
- Create and share a list of already-approved vendors and their functionalities (save time, manage the total volume of vendors).



## Al Creep

- Al functionality can come in through the front door, such as when we purchase a new, Al-specific product
- Or it might "creep" in through a side
   window or the back door, such as when
   an existing product we've purchased adds
   Al functionality (Epic, Workday).
- The key variable isn't whether the **product** or **vendor** is new, it's whether the **functionality** is new and novel to the extent that we want to have a thoughtful process to consider its potential purchase and implementation.







# Contract to protect privacy & data rights

- What data will the vendor need?
  - Will deidentified data suffice?
  - If not, consider minimum necessary
- How will your organization allow the vendor to use the data?
  - Make a conscious decision re: whether and how you will allow the vendor to use your organization's data to improve its product/model.
- With your Legal team, read the MSA, SOW, and BAA closely re: privacy-law compliance, data rights, and indemnification.
  - Press for what your organization needs.
- Protect your organization's privacy and business interests.



# Understand vendor ROI projections

- Decisions re: whether to select a product may be impacted by vendor ROI projections.
- These projections may be based on a combination of:
  - Client-specific factual inputs: how many beds do you have, how many lives, markets/regions served, payer mix, etc.;
  - Product experience: the ROI data from previous clients; and
  - Assumptions (imputed ROI): vendor may embed assumptions in the projection, e.g., results from a study or other sources.
- To assess the accuracy of the project, ask "What are all the factual inputs, actual experience, and assumptions that you used to create the ROI projection?"
- Understand <u>all</u> the elements of the calculation so your organization can perform a reasonable assessment.



## Al Product and Vendor Management: Key Takeaways

- Employ a cross-functional approach to effectively manage.
- Ask questions conduct active vendor due diligence.
- Leverage existing processes and control approaches (auditing/monitoring).
- Protect your data.
- Standard vendor management concepts still apply:
  - Keep a human-in-the-loop (with increasing automation)
  - Track performance: performance guarantees, service line agreements, ROI projections, auditing & monitoring.
- Be humble and learn challenge for all of us: to properly enable, protect, and manage risk for our organizations, we must:
  - Understand to the best extent that we can how AI products work and the issues they present; and
  - Share best practices with each other.

#### **Tufts**Medicine

# Questions?



#### **Tufts**Medicine

# Appendix





## First – consider these key business questions

#### Ask:

- What problems are we trying to solve?
- Build or buy?
- If buy, do we want this to be a
  - JV/partnership (with, e.g., economic participation), or a
  - Standard vendor engagement?
- Does an existing vendor offer this functionality (or will they)? Perform an environmental scan of your existing projects and the market.
- How would the product be incorporated into our workflows. Could it leverage existing systems or workflows? Would it require a new or adjusted workflow?

The answers will guide your strategy and negotiations.



## Assess the vendor & conduct due diligence, cont.

#### Ask questions:

- If the product utilizes an AI model "Who developed the model, your company or another company?" And "Does your company own the AI product/functionalities? If not, who does?"
- Consider the likely impact on your IT infrastructure and FTE work

   – "Would you seek to integrate the AI product/functionalities into
   any of the products/workflows we employ? If so, explain how you
   propose this would work."
- Consider vendor incentives (e.g., to get your data), vendor's privacy-law expertise/whether you trust them with your data – Could ask: "Do you have privacy counsel we can talk to?"
- Do you seek to use our data to improve your product or train your Al product/model?



# Recent Guidance: Joint Commission and Coalition for Health AI (CHAI)

#### The Responsible Use of AI in Healthcare (RUAIH)

- "The promise and opportunity of artificial intelligence (AI) tools in healthcare are transformative....The transformative opportunity that AI presents is not without risk, however."
- Describes seven elements of responsible AI use: (1) AI
   Policies and Governance Structures; (2) Patient Privacy
   and Transparency; (3) Data Security and Data Use
   Protections; (4) Ongoing Quality Monitoring; (5) Voluntary,
   Blinded Reporting of AI Safety-Related Events; (6) Risk
   and Bias Assessment; (7) Education and Training